header logo image


Page 3«..2345..1020..»

Archive for May, 2020

How Comorbidities Affect Costs and Costs Impact Nonadherence in RA – AJMC.com Managed Markets Network

Sunday, May 31st, 2020

For patients with rheumatoid arthritis (RA), cost can play a role in patient adherence to medication, but the presence of comorbidities does not impact cost of care for patients, according to 2 abstracts presented at the Virtual 2020 International Society for Pharmacoeconomics and Outcomes Research meeting.

In one study,1 researchers used a pooled cross-sectional analysis of 2009-2013 Medicare Current Beneficiary Surveydata to assess the association between drug coverage type and out-of-pocket (OOP) medication cost with cost-related nonadherence (CRN) for patients with RA in the Medicare population.

Drug coverage type included in the analysis could be no coverage, standalone Medicare prescription drug plan, Medicare Advantage Prescription Drug (MAPD) plan, prescription drug plan plus Medicaid, MAPD plus Medicaid, TRICARE, and private plans. There were 4 questions that identified CRN with either a yes or no:

Patients with MADP plus Medicaid (HR, 0.18; 95% CI, 0.05-0.71;P = .01), TRICARE (HR, 0.12; 95% CI, 0.02-0.76;P = .02), or private plans (HR, 0.43; 95% CI, 0.26-0.73;P < .01) were less likely to report CRN than those without drug coverage, the authors wrote.

In the second study,2 researchers evaluated 2140 patients with RA to understand their RA-related outpatient treatment costs. All the patients included were being treated with biologic disease-modifying antirheumatic drugsbetween April 2016 and March 2018. They were followed for 12 months.

The majority (82%) had at least 1 comorbidity. Patients with comorbidities were more likely to be older, white, female, and Medicare insured compared with patients without comorbidities. Before accounting for demographics, patients with comorbidities had higher total RA costs ($56,405 vs $49,298), but after accounting for differences in demographics using generalized linear models, the difference in costs shrunk ($52,209 vs $48,484), and after using propensity score matching (350 patients per group matched without replacement by age, race, payer, and gender), the difference in costs disappeared ($47,697 vs $47,612).

References

1. Zheng D, Thomas J. Prescription drug coverage type, out-of-pocket spending, and cost-related nonadherence among Medicare beneficiaries with rheumatoid arthritis. Presented at: ISPOR 2020; May 18-20, 2020; Abstract PMS81.https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/102115

2. Edgerton C, Radtchenko J, Holers VM. Outpatient costs in rheumatoid arthritis (RA) patients with vs without comorbidities. Presented at: ISPOR 2020; May 18-20, 2020; Abstract PMS4.https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/99754

See the original post:
How Comorbidities Affect Costs and Costs Impact Nonadherence in RA - AJMC.com Managed Markets Network

Read More...

Roche and Gilead Launch COVID-19 Trial to Test One-Two Punch of Actemra and Remdesivir – BioSpace

Sunday, May 31st, 2020

Roche and Gilead Sciences have launched a Phase III clinical trial in severe COVID-19 pneumonia, testing Roches Actemra/RoActemra with Gileads remdesivir. To date, remdesivir is the only drug shown to be effective against COVID-19 and is approved by the U.S. Food and Drug Administration (FDA) under emergency use authorization.

Actemra/RoActemra is an anti-IL-6 receptor biologic in both intravenous and subcutaneous formulations for adults with moderate-to-severe active rheumatoid arthritis (RA). It is also used to treat polyarticular juvenile idiopathic arthritis, giant cell arteritis and for chimeric antigen receptor CAR-T-cell-induced severe or life-threatening cytokine release syndrome (CRS).

ad

In other words, Actemra/RoActemra is used to treat inflammatory diseases and to control the cytokine storms associated with certain immuno-oncology treatments. Gileads remdesivir is an antiviral drug. COVID-19 is marked by several unusual symptoms, including blood clotting, cytokine storms and severe pneumonia.

As more information about COVID-19 pneumonia becomes available in these unprecedented times, it is more important than ever to work together to fight this disease, said Levi Garraway, Roches chief medical officer and head of Global Product Development. Based on our current understanding, we believe that combining an antiviral with an immune modulator could potentially be an effective approach to treating patients with severe disease. Were pleased to partner with Gilead to determine whether combining these medicines could potentially help more patients during this pandemic.

The REMDACTA Phase III trial is expected to begin enrolling in June and involve 450 patients worldwide.

Roche is also almost done with enrollment of another Phase III trial, COVACTA, studying intravenous Actemra/RoActemra alone with standard of care (SOC) compared to placebo plus SOC in hospitalized adults with severe COVID-19 pneumonia. The original design called for 330 patients but was expanded to allow for more robust data. The first patient was randomized on April 3, with about 450 patients enrolled. The company expects to share data from the COVACTA trial sometime this summer. The protocol for COVACTA allows patients who were treated with antiviral drugs, including experimental antivirals, so data from that subgroup can be used to supplement the COVACT study.

COVACTA is being run in partnership with the FDA and the Biomedical Advanced Research and Development Authority (BARDA). Roche is also taking part in the Accelerated COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership led by the National Institutes of Health (NIH) and the Foundation of the NIH.

As mentioned above, in a study conducted by the U.S. National Institute of Allergy & Infectious Diseases (NIAID) of remdesivir in 1,063 COVID-19 patients, the drug showed on April 30 that patients recovered from the disease faster than patients who received placebo. This prompted the emergency use authorization by the FDA within days. What it showed was patients had a 31% faster time to recovery than the placebo group, from a median 15 days to a median 11 days.

The detailed data was published yesterday in The New England Journal of Medicine. Additional data suggested remdesivir was a little bit better in decreasing deaths than were originally reported, although the difference wasnt statistically significant. Previously, death rates were 8% with the drug compared to 11.6% in the placebo groups. With additional two-week data, the rate for remdesivir was 7.1% compared to 11.9% for the placebo.

In a note to clients written on Saturday, May 23, Geoffrey Porges, analyst with SVB Leerink, said the numeric mortality improvement, if further validated, can change sentiment about COVID-19. In addition, the improvement can take some of the stress off hospital systems.

The drug didnt seem to provide much help to COVID-19 patients with mild or moderate disease and patients on invasive ventilation or extracorporeal membrane oxygenation were almost identical in both arms of the trial. The likelihood in improvement in clinical status was 50% higher in patients receiving remdesivir than in the placebo cohort.

Porges wrote, It is likely that the treatment benefit from remdesivir will increase in the real world once the lessons of this trial and other studies are incorporated into routine treatment practices.

Umer Raffat, an analyst with Evercore noted of the published study data, The single most important data disclosure that I was awaiting was this: How does mortality look different in patients that take remdesivir early? These early trials on COVID are all about identifying not only whether a drug works, but also when to initiate the drug.

Read more here:
Roche and Gilead Launch COVID-19 Trial to Test One-Two Punch of Actemra and Remdesivir - BioSpace

Read More...

Assessing the Fallout From the Coronavirus Pandemic Systemic Idiopathic Juvenile Arthritis Treatment Market To Grow Significantly From 2020 To 2026,…

Sunday, May 31st, 2020

The Systemic Idiopathic Juvenile Arthritis Treatment market research encompasses an exhaustive analysis of the market outlook, framework, and socio-economic impacts. The report covers the accurate investigation of the market size, share, product footprint, revenue, and progress rate. Driven by primary and secondary researches, the Systemic Idiopathic Juvenile Arthritis Treatment market study offers reliable and authentic projections regarding the technical jargon.All the players running in the global Systemic Idiopathic Juvenile Arthritis Treatment market are elaborated thoroughly in the Systemic Idiopathic Juvenile Arthritis Treatment market report on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines R&D developments, legal policies, and strategies defining the competitiveness of the Systemic Idiopathic Juvenile Arthritis Treatment market players.The report on the Systemic Idiopathic Juvenile Arthritis Treatment market provides a birds eye view of the current proceeding within the Systemic Idiopathic Juvenile Arthritis Treatment market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Systemic Idiopathic Juvenile Arthritis Treatment market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2534385&source=atm

The following manufacturers are covered:Alteogen Inc.Bristol-Myers Squibb CompanyEpirus Biopharmaceuticals, Inc.Johnson & JohnsonMomenta Pharmaceuticals, Inc.Mycenax Biotech Inc.Novartis AGOncobiologics, Inc.

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeAdalimumab BiosimilarCanakinumabGolimumabTocilizumab BiosimilarOthers

Segment by ApplicationClinicHospitalOthers

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2534385&source=atm

Objectives of the Systemic Idiopathic Juvenile Arthritis Treatment Market Study:To define, describe, and analyze the global Systemic Idiopathic Juvenile Arthritis Treatment market based on oil type, product type, ship type, and regionTo forecast and analyze the Systemic Idiopathic Juvenile Arthritis Treatment market size (in terms of value and volume) and submarkets in 5 regions, namely, APAC, Europe, North America, Central & South America, and the Middle East & AfricaTo forecast and analyze the Systemic Idiopathic Juvenile Arthritis Treatment market at country-level for each regionTo strategically analyze each submarket with respect to individual growth trends and their contribution to the global Systemic Idiopathic Juvenile Arthritis Treatment marketTo analyze opportunities in the market for stakeholders by identifying high growth segments of the global Systemic Idiopathic Juvenile Arthritis Treatment marketTo identify trends and factors driving or inhibiting the growth of the market and submarketsTo analyze competitive developments, such as expansions and new product launches, in the global Systemic Idiopathic Juvenile Arthritis Treatment marketTo strategically profile key market players and comprehensively analyze their growth strategiesThe Systemic Idiopathic Juvenile Arthritis Treatment market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the Systemic Idiopathic Juvenile Arthritis Treatment market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the Systemic Idiopathic Juvenile Arthritis Treatment market study provides reliable and authentic projections regarding the technical jargon.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2534385&licType=S&source=atm

After reading the Systemic Idiopathic Juvenile Arthritis Treatment market report, readers can:Identify the factors affecting the Systemic Idiopathic Juvenile Arthritis Treatment market growth drivers, restraints, opportunities and trends.Examine the Y-o-Y growth of the global Systemic Idiopathic Juvenile Arthritis Treatment market.Analyze trends impacting the demand prospect for the Systemic Idiopathic Juvenile Arthritis Treatment in various regions.Recognize different tactics leveraged by players of the global Systemic Idiopathic Juvenile Arthritis Treatment market.Identify the Systemic Idiopathic Juvenile Arthritis Treatment market impact on various industries.

Excerpt from:
Assessing the Fallout From the Coronavirus Pandemic Systemic Idiopathic Juvenile Arthritis Treatment Market To Grow Significantly From 2020 To 2026,...

Read More...

Can coronavirus affect eyesight? Evidence is lacking, say experts – The Guardian

Sunday, May 31st, 2020

Speaking to the press on Monday, Dominic Cummings said he drove, with his wife and child, on a 30-mile trip to Barnard Castle during lockdown to see if he could drive safely, concerned that his eyesight might have been affected by coronavirus.

In a press conference later the same day, Boris Johnson also claimed to have experienced problems with his eyesight following Covid-19, brandishing a pair of glasses and saying: Im finding that I have to wear spectacles for the first time in years I think thats very, very plausible that eyesight can be a problem associated with coronavirus.

Eye problems are not on the UKs list of coronavirus symptoms. At present, only a high temperature, new continuous cough, and loss of taste or smell are considered common signs of the disease.

A spokesperson for Moorfields eye hospital, in London, said there was, at present, very little evidence to suggest Covid-19 could affect eyesight.

Cases where Covid-19 is recorded alongside an impact on eyesight are rare, so we cannot establish a direct causal effect, the spokesperson said.

Prof Chris Hammond, Frost chair of ophthalmology at Kings College London, who is also a consultant ophthalmologist at Guys and St Thomas NHS trust, said: Eye problems with coronavirus, Covid-19, seem to be extremely uncommon and there arent any reports that I can find in the literature of anyone having visual loss due to the virus.

Maybe something like one in 100 people may get a bit of conjunctivitis, which can in theory blur vision. But it is pretty uncommon. He added that such eye problems were more frequent among patients who had been ventilated.

Conjunctivitis is an inflammation of the thin layer of tissue that covers the eye, and typically has symptoms including pinkness of the eye, watering and a sticky discharge.

Robert MacLaren, the professor of ophthalmology at the University of Oxford, said reports from Wuhan suggested a link between Covid-19 and conjunctivitis, as well as conjunctival hyperemia (red eye), chemosis (eye swelling), epiphora (watery eye) and increased secretions (sticky eye). MacLaren noted such symptoms could affect vision.

A spokesperson for the Royal College of Ophthalmologists said the college was unable to report on an association of vision impairment with Covid-19 due to the lack of evidence. But, they added, the college had previous noted coronavirus might cause conjunctivitis.

Hammond said it would be clear to an individual if they had conjunctivitis. You would be aware that you had a bit of a pink eye and it was a bit watery and discharging. A bit like a windscreen wiper on a car, you have to blink to clear the muck off the tear film.

Hammond said a report from Brazil suggested that, from scans, some Covid-19 patients appeared to have some damage to the retina, but the patients did not have any symptoms of eye problems or loss of vision.

Hammond added that severe Covid-19 might mean patients needed their reading glasses more.

It is true when you have been significantly unwell, that as all your muscles are a bit weaker, the muscles that control the focus of your eyes can be weaker, he said. But the situation, he noted, applied only to far-sighted people, adding that Cummings appeared to wear glasses for short-sightedness myopia being unable to see well in the distance.

As for getting behind the wheel of the car to test your eyesight, Hammond said the Highway Code stated that drivers needed to be able to read a vehicle number plate at a minimum distance of 20 metres. When you have your driving test to see if you are seeing well enough to be allowed to drive, they test whether you can read the number plate before they allow you in the car, he said.

Continued here:
Can coronavirus affect eyesight? Evidence is lacking, say experts - The Guardian

Read More...

PM and top aide say coronavirus affected their eyesight – ITV News

Sunday, May 31st, 2020

Prime Minister Boris Johnson has said that his own eyesight was affected by coronavirus, after his top aide said he had gone on a drive to test his vision after recovering from the virus.

Mr Johnson told the daily Downing Street press briefing on Monday that he was having to wear glasses for the first time in years after suffering coronavirus.

He added: Im finding that I have to wear spectacles for the first time in years because I think of the likely effects of this thing so Im inclined to think theres some I think thats very, very plausible that eyesight can be a problem associated with coronavirus.

His comments come after Mr Cummings earlier told reporters that he took his family to Barnard Castle to see if he could drive safely after his illness affected his eyesight.

But the chair of the Police Federation of England and Wales took to social media to warn people not to get behind the wheel if they feel unwell or their eyesight is impaired.

Speaking at a press conference in the Downing Street rose garden, Mr Cummings said he had fallen ill with Covid symptoms of a headache and fever the day after arriving in Durham.

After recovering, Mr Cummings said he got expert medical advice and was told he could go back to work.

But because the virus had affected his eyesight, he said his wife did not want to risk the drive back to London and they agreed they should go for a short drive.

Mr Cummings added: My wife was very worried, particularly as my eyesight seemed to have been affected by the disease.

She did not want to risk a nearly 300-mile drive with our child given how ill I had been.

We agreed that we should go for a short drive to see if I could drive safely, we drove for roughly half an hour and ended up on the outskirts of Barnard Castle town.

We did not visit the castle, we did not walk around the town.

We parked by a river. My wife and I discussed the situation, we agreed that I could drive safely, we should turn around and go home.

But the national chair of the Police Federation of England and Wales John Apter took to Twitter to advise people to not drive if their eyesight might be impaired.

Sorry, this content isn't available on your device.

He added: Folks, I say this in all sincerity and as an important road safety issue.

If youre feeling unwell and your eyesight may be impaired do not drive your vehicle to test your ability to drive. Its not a wise move.

As a former road death investigator with Hampshire police I have investigated many serious collisions, including fatalities.

Some of these were caused by drivers with impaired vision, this is a serious issue.

Do not drive if your eyesight is impaired or you feel unwell.

Surrey Polices road policing unit also tweeted that anyone concerned about their eyesight should not drive.

Sorry, this content isn't available on your device.

It added: A drivers vision is very important.

If you have any concerns about your eyesight dont drive, until youve sought the advice of a qualified optician.

A driver must be able to read a standard number plate from 20 metres.

Read more:
PM and top aide say coronavirus affected their eyesight - ITV News

Read More...

Bright future: VitaHealth eyes growing opportunity with vision care supplements as screen time soars – FoodNavigator-Asia.com

Sunday, May 31st, 2020

Singapore is often labelled myopia capital of the world, with Dr Lam Pin Pin, Singapores Senior Minister of State for Health stating the prevalence is 65% in primary school students, and rises to 83% in young adults.

By 2050, it is projected that 80 to 90% of all Singaporean adults above 18 years old will be myopic and 15 to 25% of these individuals may have high myopia, he said.

He explained that high myopia increases the risk of eye disorders later in life, such as early cataracts, glaucoma and macular degeneration.

In light of this,Beh Kheng Suan, country head of Malaysia and Singapore at VitaHealthobserved: We see a change in customer behavior. Nowadays, it is not only the older group of people who are looking for eye care supplements to improve their eyesight. Younger customers are also looking for eye care supplements due to long hours of staring at their screens, which can cause dry and tired eyes.

In particular, she pointed out that eye care was especially important for I-gen (4-16 years old) and millennials (17-34 years old) as these groups were most prone to myopia and digital eye fatigue.

VitaHealth currently has four products in its eye care line. It also markets health supplements with functions ranging from joint, liver, cardiovascular to blood sugar control.

Behtold NutraIngredients-Asia that eye supplements were among the top five categories sold in Singapore, and she expects sales to grow between 10 to 15% year-on-year.

Last year, the firm launched Eye-Pro, a supplement claiming to offer blue light protection. According to Beh, Eye-Pro is the first eye care formula in Singapore containing meso-zeaxanthin.

Beh explained that the macula in eyes is responsible for sharp and detailed central vision. It is largely made up of three xanthophyll carotenoids, lutein, zeaxanthin and meso-zeaxanthin, collectively known as the macular pigment.

Of the three carotenoids, meso-zeaxanthin has the greatest capability of quenching oxygen radicals. It has the highest capacity to filter the most energetic and potentially damaging wavelengths of visible light, and to neutralise free radicals, she said.

The supplement is formulated with XanMax, a patented marigold flower ingredient manufactured by Indias Katra PhytoChem.

For every 200mg of XanMax, there is 20mg of lutein and 4mg of trans-meso zeaxanthin. Trans-meso zeaxanthin refers to total zeaxanthin comprising of both trans- and meso- isomers.

In a clinical study, supplementation of XanMax for six months was found to increase macular pigment optical density and serum lutein concentration.

This macular pigment acts as internal sunglasses to protect the photoreceptor cells in the retina against harmful light and improve vision. In combination, lutein, zeaxanthin and meso-zeaxanthin provide the most potent antioxidants that can localise to the macula and represent the natural oxidative protectant, Beh explained.

With the Covid-19 pandemic resulting in many people working remotely, she said the firm had seen sales of Eye-Pro picking up. There is an increase in Eye-Pro sales as many people are working from home and spending more hours staring at a computer screen. This product helps to protect vision from the damaging effects of blue light emitted by digital devices.

VitaHealths supplements are sold on its official website, as well as other e-commerceplatforms including Lazada, Shopee and Qoo10. Its offline presence includes departmental stores, pharmacies, hospitals and polyclinics.

In terms of trends in eye care ingredients, Beh said lutein, zeaxanthin and bilberry would continue to remain popular.

The globaleye health supplements market is expected to grow from USD1,412.12m in 2018 to USD2,116.12m by 2025 at a CAGR of 5.94%.

Original post:
Bright future: VitaHealth eyes growing opportunity with vision care supplements as screen time soars - FoodNavigator-Asia.com

Read More...

Coronavirus: The drive-through that protects glaucoma sufferers – BBC News

Sunday, May 31st, 2020

At first glance, the sign may appear to say "10p drive-through," - but this is the Belfast Trust's Intra-Ocular Pressure drive-through clinic.

It is a first in the UK, helping to protect the eyesight of glaucoma sufferers during the Covid-19 pandemic.

"Glaucoma is a condition that affects the nerve at the back of the eye," consultant ophthalmic surgeon Angela Knox explained.

"It causes loss of peripheral vision in the early stages, which is irreversible, and that can lead on to tunnel vision or loss of central vision in the advanced stages.

"The treatment for it is usually with eye drops which are taken on a daily basis to lower the pressure in the eye, but laser and surgery can also be carried out."

First to pull into the marquee is Thomas Taylor.

He has had the condition for much of the last 20 years. He didn't know his sight was so bad until glaucoma was diagnosed.

"I was as blind as a bat," he said, from the comfort of his daughter's car.

"They checked me last September, and the professor said: 'I'm not happy with this left eye'.

Thomas has had to have operations help restore some of his sight.

Last year, he was prescribed new eye drops, and he's back to have his eyes checked, driven to the Shankill Wellbeing and Treatment centre by his daughter.

Under the canvas of the marquee, Thomas stays in his daughter's car.

The nurse, Sarah Henderson, asks him to remove his seatbelt and turn towards her.

From beside the car, in her visor, mask, apron and gloves, she uses a portable pressure device to assess how his eyes are doing.

Using just her gloved thumb and forefinger on one hand, she touches Thomas' forehead lightly to support the machine, for the pressure reading to be carried out.

It's over in seconds.

He'll get a phone call in a few days' time to let him know the result and any action that needs to be taken.

"Our patients seem to be very pleased with it and we've had a very good feedback," said Sister Henderson.

"Some of our patients are a little bit anxious at the minute about coming up to the clinic, and rightly so, just because of the current climate that we're in.

"So this is a really good way of reassuring patients, taking their pressure for them, making sure treatment is working and being able to give them a little bit of feedback and let them know how things are going.

"We're finding it works very well, and we're able to see a lot more patients than we would normally be able to see, which is also beneficial for us," she added.

Consultant Angela Knox and her team have identified hundreds of patients who can be monitored this way during the pandemic.

"It's not suitable for all of our patients because many of our patients need additional tests to monitor their glaucoma.

"For these patients where we just need to know their pressure, it's been a great way of providing the service for them," she said.

"It also keeps our waiting area free for patients that we need to see face to face," she added.

For the steady stream of patients like Thomas arriving for their checks, the reassurance that their sight is being kept safe while they are protected from any exposure to the virus is invaluable.

"It's very convenient to come here, you know," said Thomas.

"I don't have to worry about the clinic. And hopefully I get checked out and Bob's your uncle."

See the article here:
Coronavirus: The drive-through that protects glaucoma sufferers - BBC News

Read More...

Bhopal MP Pragya Thakur Claims Her Vision Impaired in One Eye, 25% Vision left in The Other – News18

Sunday, May 31st, 2020

File photo of BJP MP Pragya Singh Thakur. (PTI)

A day after her missing posters dotted areas in her Lok Sabha constituency Bhopal, BJP MP Pragya Thakur said she has no vision in one eye and only 25% eyesight in the second. Thakur in a video message said she has been recuperating at AIIMS in New Delhi for a while.

In a video message, Thakur with a bandaged left eye claimed her condition deteriorated in the last month or so and she cant see from one eye and has blurred vision in the second. "I have swelling right from brain to retina. I am not in a position to talk much," she said.

She lashed at those who put up her missing posters in Bhopal saying she does not care for those who only believe in politics and added that her representatives are offering services to public in Bhopal.

"I believe in working and I may be ill but this illness is also a gift of Congress party," said the first-time MP who had defeated senior Congress leader Digvijaya Singh.

Thakur has blamed custodial torture for her numerous physical ailments and claims she was harassed in connection to the Malegaon blasts at the behest of Congress leaders. Her missing posters were put up by unknown persons in several areas in Bhopal on Friday.

https://pubstack.nw18.com/pubsync/fallback/api/videos/recommended?source=n18english&channels=5d95e6c378c2f2492e2148a2&categories=5d95e6d7340a9e4981b2e10a&query=Bhopal,MP,Pragya,Thakur,Claims,Her,Vision,Impaired,in,One,Eye,,25%,Vision,left,in,The,Other,Bhopal,MP,madhya,pradesh,&publish_min=2020-05-29T12:12:46.000Z&publish_max=2020-05-31T12:12:46.000Z&sort_by=date-relevance&order_by=0&limit=2

Visit link:
Bhopal MP Pragya Thakur Claims Her Vision Impaired in One Eye, 25% Vision left in The Other - News18

Read More...

Are you listening Dominic Cummings? Drivers urged to avoid getting behind the wheel if concerned about their eyesight – The Voice Online

Sunday, May 31st, 2020

ROAD SAFETY organisation GEM Motoring Assist is urging drivers to avoid getting behind the wheel if they have any concerns about their eyesight.

During recent months, with routine eyesight tests hard or impossible to come by, some drivers may have become aware of changes in their vision, and GEM is asking them to do the responsible thing and avoid driving.

GEM road safety officer Neil Worth said: GEM has long campaigned for more rigorous and routine eyesight testingin the interests of road safety.

A proper eye test will also measure peripheral awareness, eye coordination, depth perception, ability to focus and colour vision.

If you are concerned about changes to the quality of your vision, please dont put yourself and others at risk by driving. Instead wait to have a propereyesight test before you get behind the wheel.

There are simply no excuses fordriving when youreunsure you can see properly, as you risk causing injury not only to yourself but to your passengers and anyone else who happens to be in your way.

Poor eyesight is linked to more than 3,000 fatal and serious injury collisions every year.We believe all drivers should have an eye test every two years, just to ensure there are no safety concerns about their vision and to deal with any developing issues at an early stage.

The current eyesight test was introduced to the driving test in 1937 and has only been amended in minor ways over the years to reflect changing number plate sizes. It is the only eyesight test drivers are required to undertake until they reach the age of 70.

According to GEM, the test is crude and outdated, as it only measures visual acuity (sharpness). It could also quite easily examine a drivers field of view, as is done in many US states, to check whether motorists can see and react to whats happening around them.

Worth adds: Asking someone to read a number plate at 20.5 metres (67 feet) cannot on its own be a measure of their fitness to continue driving.

A proper eye test will also measure peripheral awareness, eye coordination, depth perception, ability to focus and colour vision. Before getting back on the road after lockdown, we encourage every driver with any eyesight concerns to book a test and ensure everything is in order.

Eyesight has until now not been a major consideration for those who may have contracted coronavirus.

The possibility thatCovid-19 may have an affect on eyesight has been in the spotlight after prime minister Boris Johnsons chief adviser Dominic Cummings attempted to explain to the nation why he had driven to a local beauty spot during his controversial visit to Durham which came at the height of the coronavirus lockdown.

Follow GEM on Twitter @MotoringAssist for the latest industry news.

Read the original here:
Are you listening Dominic Cummings? Drivers urged to avoid getting behind the wheel if concerned about their eyesight - The Voice Online

Read More...

Bad conspiracy theories: The bad, the worse and the ugliest – The Spectrum

Sunday, May 31st, 2020

Leigh Washburn, My Turn Published 6:57 a.m. MT May 30, 2020

Leigh Washburn(Photo: SUBMITTED)

A recent BBC report (https://www.bbc.com/news/stories-52731624) graphically describes the consequences of unchecked propagation of mis- and disinformation about SARS-Cov-2: The hospitalized couple, one near death, in Florida, believing it was a hoax; violence against Muslims in India; people swallowing fish tank cleaner, disinfectants, or toxic alcohol; and the worst and most common those waiting too long to seek help because they thought the hazards were overblown (https://www.erinbromage.com/post/the-risks-know-them-avoid-them).

Conspiracy theories are more than just distracting. Deciding who to trust isnt easy, but its possible and essential. Ask whos talking. Whats their background, their reputation? Are they writing for a known outlet? Is the piece sensationalist? Contradictory? Do reporters interview multiple people actual experts vet sources, fact-check, question inconsistencies (The Conspiracy Theory Handbook; Yahoo News, 05/22/20; Forbes, 05/08/20; Atlantic, 03/21/20; Lifehacker, 05/08/20)?

The most recent, and arguably worst, is the slick documentary, Plandemic, which looks and feels credible but doesnt hold up under careful scrutiny. Its been fact-checked by several experts (Science, 05/08/20; factcheck.org, 05/08/20; https://respectfulinsolence.com/2020/05/06/judy-mikovits-pandemic/; NPR;05/08/20). Too much is just off.

Its sole interviewee, Judy Mikovits, is introduced as one of the most accomplished scientists of her generation. So who is she? She earned a BS in chemistry in 1980, worked as a lab technician until 1988, got her PhD in biochemistry and molecular biology in 1991, then apparently held postdoctoral positions until 2006, when she was tapped to head a new private institute founded by the Whittemore family to look for a viral cause of chronic fatigue syndrome (CFS). First red flag she was apparently a lab tech or a postdoc for more than 20 years, all that time working on other investigators projects under their supervision. She was never an independent researcher (respectfulinsolence.com., 05/06/20).

Her inexperience caught up with her. An article in the prestigious journal Science, in which she claimed to have discovered a CFS-related virus, was retracted because blood samples were contaminated (Science, 12/23/11). She lost her job and was ultimately arrested (NOT by SWAT) for stealing lab notebooks and other data. Those charges were eventually dropped although the institute won a civil suit.

She makes vague claims that Anthony Fauci blocked publication of some work she did as a technician (implausible); that her research on HIV was instrumental in developing treatments (unverified); and that Fauci and Big Pharma destroyed her career, without explaining how.

Her recorded comments display big gaps in scientific knowledge. A few examples:

This is just a preview. The articles I cited above explore these and many more red flags in depth, with plenty of solid science. They make for good reading, especially if youre still having trouble making up your mind.

Leigh Washburn is a member of the Iron County Democrats.

Read or Share this story: https://www.thespectrum.com/story/news/2020/05/30/my-turn-bad-conspiracy-theories-bad-worse-and-ugliest/5290567002/

View original post here:
Bad conspiracy theories: The bad, the worse and the ugliest - The Spectrum

Read More...

Creepy organizations: These groups are the definition of a cult – Film Daily

Sunday, May 31st, 2020

Just like hate, cult is a strong word that some organizations definitely do not want to use to define themselves. Heavens Gate didnt call themselves a cult, and neither did the Branch Davidians. But for the rest of time, these groups will be remembered as the definition of a cult.

At some point or another, well be remembering these groups as cults as well. Just because theyre not called cults doesnt mean theyre definition not cult-like. Heck, past members of these organizations may even call these groups cults themselves.

Look, we dont care how many explanations youve gotten from your high school friend selling essential oils or diet products. MLMs are pyramid schemes that have a cult like energy from them. Just look at a MLM convention to prove the cult atmosphere.

Sure, back in the day, companies like Pampered Chef, Avon, and Mary Kay were MLMs that actually let people be fairly successful in a side gig. But the explosion of MLMs in the past 20 years has proven that this is no longer a successful business practice for people. All theyre left with is fake friends that will ditch them the minute they stop making their monthly goals.

This is on the same level of people who are actually convinced reptiles run our governments. This French religious group preaches that extraterrestrials created humanity through genetic engineering, and their representatives have come to Earth in the form of figures such as Jesus Christ and Budda.

Granted, we have to give them some credit as they preach a message of peace on Earth. Though, they want world peace so the extraterrestrial overloads will come back to Earth and visit humans at the embassies built by Ralismists.

If youre familiar with Parks and Rec, this Ron Swanson but literally no connection to the outside world. The Brethren join under the understanding that to prepare for the end of the world, they need to give up all belongings and live off the land until the end.

Theres also no celebrations or playing within the Brethren as they believe such celebrations should be saved for the return of the savior when the world ends. Unfortunately, if someone joins the Brethren, oftentimes theyll leave their family and friends behind with no warning, leading to many Brethren members having missing persons notices out on them.

While the group has gone through rebranding over the years, the stories children raised in the cult tell, including Rose McGowan, and the Phoenix children (River, Joaquin, Rain, and Summer) have us concerned regardless.

The organization believes theyre in a sexual relationship with Jesus, and uses sex in their teachings of Gods love and mercy. Initially, it was a big hit for converts, but it allegedly also caused several cases of child sexual abuse throughout the many communes of TFI.

Probably the most famous modern day cult, Scientology promotes itself as a religious organization based on scientific research. But then you realize this is the same organization that believes humans can live multiple lives, humans are immortal, and humans possess infinite capabilities.

And now you understand why Tom Cruise does such insane stunts in Mission Impossible, because he doesnt think hell die ever. But the organization is well known for keeping its practices secret and basically getting ready to attack anyone who says a bad thing about the organization. So if our website goes down, you know why.

Excerpt from:
Creepy organizations: These groups are the definition of a cult - Film Daily

Read More...

Researchers find new selective-breeding method for heat-tolerant abalone without genetic modification – Aju Business Daily

Friday, May 29th, 2020

[Courtesy of the Ministry of Oceans and Fisheries]

More than 7,500 tons of abalone are consumed annually in South Korea. However, it's not easy for abalone farmers to keep their prized product alive during summer as the shellfish die easily when the sea temperature rises above 32 degrees Celsius (89.6 degrees Fahrenheit). To increase the production of abalone by increasing survivability in warm water temperatures, some farmers in China and other countries use genetic modification.

Temperatures of the sea around the Korean peninsula showed abnormality due to global warming, rising on an average of 0.44 degrees Celsius every year over the last decade, according to the Korea Meteorological Administration. Abalone farmers lost more than 13.6 billion won ($10 million) in 2018 due to high sea temperatures.

The National Institute of Fisheries Science (NIFS), a scientific body operated by the Ministry of Oceans and Fisheries, said in a statement that it has found a selective breeding method that involves no genetic engineering by using genetic markers. The institute will commercialize the method after a pilot project at actual abalone farms.

"With the recent trend of rising sea temperature, the future of abalone farms depends on developing breeds that can survive in places where the water temperature varies greatly," NIFS researcher Nam Bo-hye was quoted as saying.

Based on the institute's 2014 finding that a certain breed of abalone is capable of staying alive in seas warmer than 32 degrees Celsius, NIFS researchers have analyzed genetic characteristics, which are genetic markers, of the more heat-tolerant breed. Abalone farmers can check genetic markers to sort out the heat-tolerant breed in a simple and quick manner.

Excerpt from:
Researchers find new selective-breeding method for heat-tolerant abalone without genetic modification - Aju Business Daily

Read More...

Ethicists: We need more flexible tools for evaluating gene-edited food – The Conversation US

Friday, May 29th, 2020

Is there now a way to genetically engineer crops to create food that people can confidently consider natural?

Gene-editing technology sounds like it might offer this possibility. By altering an organisms genetic material, or genome, without introducing genes from other species, advocates of genome editing argue the technique can sidestep most of the difficult ethical and regulatory challenges plaguing organisms with added transgenes, which are genes from other species. Some even argue these cisgenic products are natural enough to count as organic.

As ethicists specializing in how technology alters human-nature relations, we can understand why advocates see the ethics this way. If crossing species lines is the measure of whether a technique counts as natural or not, then genome editing appears to have the potential to pass a naturalness test.

Genome editing, its boosters say, can make changes that look almost evolutionary. Arguably, these changes could have happened by themselves through the natural course of events, if anyone had the patience to wait for them. Conventional breeding for potatoes resistant to late blight is theoretically possible, for example, but it would take a lot of time.

Although we understand the potential advantages of speed, we dont think an ethics hinging on the idea of cisgenesis is adequate. We propose a better ethical lens to use in its place.

Our work is part of a four-year projectfunded by the Norwegian Research Council scrutinizing how gene editing could change how we think about food. The work brings together researchers from universities and scientific institutes in Norway, the U.K. and the U.S. to compare a range of techniques for producing useful new crops.

Our project is not focused on the safety of the crops under development, something that obviously requires concerted scientific investigation of its own. Although the safety of humans and the health of the environment is ethically crucial when developing new foods, other ethical issues must also be considered.

To see this, consider how objections against genetically modified organisms go far beyond safety. Ethical issues around food sovereignty range broadly across farmer choice, excess corporate power, economic security and other concerns. Ethical acceptability requires a much higher bar than safety alone.

Although we believe gene editing may have promise for addressing the agricultural challenges caused by rising global populations, climate change and the overuse of chemical pesticides, we dont think an ethical analysis based entirely on crossing species lines and naturalness is adequate.

It is already clear that arguing gene-edited food is ethical based on species lines has not satisfied all of gene editings critics. As Ricarda Steinbrecher, a molecular biologist cautious about gene editing, has said, Whether or not the DNA sequences come from closely related species is irrelevant, the process of genetic engineering is the same, involving the same risks and unpredictabilities, as with transgenesis.

Comments of this kind suggest talking about species lines is an unreliable guide. Species and subspecies boundaries are notoriously infirm. Charles Darwin himself conceded in Origin of Species, I look at the term species, as one arbitrarily given for the sake of convenience to a set of individuals closely resembling each other.

The 2005 edition of the Mammal Species of the World demonstrated this arbitrariness by collapsing all 12 subspecies of American cougars down to one Puma concolor cougar overnight. In 2017, the Cat Classification Task Force revised the Felidae family again.

If species lines are not clear, claiming naturalness based on not crossing species lines is, in our view, a shaky guide. The lack of clarity matters because a premature ethical green light could mean a premature regulatory green light, with broad implications for both agricultural producers and consumers.

We think a more reliable ethical measure is to ask about how a technique for crop breeding interferes with the integrity of the organism being altered.

The term integrity already has application in environmental ethics, ecology, cell biology, interhuman ethics, organic agriculture and genetics.

A unifying theme in all these domains is that integrity points toward some kind of functional wholeness of an organism, a cell, a genome or an ecological system. The idea of maintaining integrity tracks a central intuition about being cautious before interfering too much with living systems and their components.

The integrity lens makes it clear why the ethics of gene editing may not be radically different from the ethics of genetic modification using transgenes. The cell wall is still penetrated by the gene-editing components. The genome of the organism is cut at a site chosen by the scientist, and a repair is initiated which (it is hoped) will result in a desired change to the organism. When it comes to the techniques involved with gene editing a crop or other food for a desired trait, integrity is compromised at several levels and none has anything to do with crossing species lines. The integrity lens makes it clear the ethics is not resolved by debating naturalness or species boundaries.

Negotiation of each others integrity is a necessary part of human-to-human relations. Adopted as an ethical practice in the field of biotechnology, it might provide a better guide in attempts to accommodate different ethical, ecological and cultural priorities in policymaking. An ethic with a central place for discussion of integrity promises a framework that is both more flexible and discerning.

As new breeding techniques create new ethical debates over food, we think the ethical toolbox needs updating. Talking about crossing species lines simply isnt enough. If Darwin had known about gene editing, we think he would have agreed.

[Deep knowledge, daily. Sign up for The Conversations newsletter.]

See original here:
Ethicists: We need more flexible tools for evaluating gene-edited food - The Conversation US

Read More...

Genetic Engineering Market 2020 Reflect Impressive Expansion by Integrated DNA Technologies, Thermo Fisher Scientific, Merck KGaA, Horizon Discovery…

Friday, May 29th, 2020

Genetic Engineering Market research added by the insight partners, offers a comprehensive analysis of growth trends prevailing in the global business domain. This report also provides definitive data concerning market, size, commercialization aspects and revenue forecast of the Genetic Engineering industry. In addition, the study explicitly highlights the competitive status of key players within the projection timeline while focusing on their portfolio and regional expansion endeavours.

This report on Genetic Engineering Market delivers an in-depth analysis that also comprises an elaborate assessment of this business. Also, segments of the Genetic Engineering Market have been evidently elucidated in this study, in addition to a basic overview pertaining to the markets current status as well as size, with respect to the profit and volume parameters. The study is ubiquitous of the major insights related to the regional spectrum of this vertical as well as the companies that have effectively gained a commendable status in the Genetic Engineering Market.

Get the inside scope of the Sample report @https://www.theinsightpartners.com/sample/TIPRE00004544/

MARKET INTRODUCTION

A gene is the basic physical and function unity of heredity. Genetic engineering is the changing the structure of the genes of a living things in order to make it healthier, stronger and more useful to human. Changing DNA in cell is to understand their biology. Genetic engineering are currently used in both animal and plant cells this modifications are helps to improve performance of cell.

MARKET DYNAMICS

The genetic engineering market is expected to grow during the forecast period due to rising use of genetic engineering in the field of medical as well as in agriculture, high prevalence of infectious disease and awareness of steam cell therapy, and increasing no of genomics project due to government raising funds in genetic engineering field and more R&D. Thus, various governments are taking initiatives to create awareness amongst people about genetic engineering.

The report also includes the profiles of key Genetic Engineering Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

Key Competitors In Market are

Integrated DNA Technologies, Thermo Fisher Scientific, Merck KGaA, Horizon Discovery Group, Transposagen Biopharmaceuticals, New England Biolabs, Genscript Biotech Corporation, Lonza Group, Origene Technologies, Sangamo Therapeutics

TOC pointsof Market Report:

Market size & shares

Market trends and dynamics

Market Drivers and Opportunities

Competitive landscape

Supply and demand

Technological inventions in industry

Marketing Channel Development Trend

Market Positioning

Pricing Strategy

Brand Strategy

Target Client

MARKET SCOPE

The Global Genetic Engineering Market Analysis to 2027 is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of Genetic Engineering Market with detailed market segmentation by product type, drug class, and geography. The global genetic engineering market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading genetic engineering market players and offers key trends and opportunities in the market.

Market segmentation:

Genetic Engineering Market to 2027 Global Analysis and Forecasts by Technology (CRISPR, TALEN, ZFN, Antisense, Other Technologies); By Application (Cell line Engineering, Genetic Engineering, Diagnostics & Therapeutics); By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations) and Geography

By Geography North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. And 13 countries globally along with current trend and opportunities prevailing in the region.

The target audience for the report on the market

Manufactures

Market analysts

Senior executives

Business development managers

Technologists

R&D staff

Distributors

Investors

Governments

Equity research firms

Consultants

Key Questions Answered

How big will the market for Genetic Engineering be in 2027? What is the current CAGR of the Genetic Engineering Market? Which product is expected to have the highest market growth? Which application should be used to win a large part of the market for Genetic Engineering ? Which region is likely to offer the most opportunities on the Genetic Engineering Market? Will the market competition change in the forecast period? Who are the main players currently active in the global Genetic Engineering Market? How will the market situation change within the coming years? What are the usual commercial tactics for players? What is the growth perspective of the global Genetic Engineering Market?

Answering these types of questions can be very useful for gamers to clear up their doubts as they implement their strategies to grow in the global Genetic Engineering Market. The report provides a transparent picture of the actual situation in the global Genetic Engineering Market so that companies can work more effectively. It can be tailored to the needs of readers to better understand the global market for Genetic Engineering.

Click to buy full report with all description:-https://www.theinsightpartners.com/buy/TIPRE00004544/

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

Go here to see the original:
Genetic Engineering Market 2020 Reflect Impressive Expansion by Integrated DNA Technologies, Thermo Fisher Scientific, Merck KGaA, Horizon Discovery...

Read More...

global market for viral vector and plasmid manufacturing is predicted to grow at a CAGR of 16.28% over the forecast period of 2020-2030 – Olean Times…

Friday, May 29th, 2020

NEW YORK, May 28, 2020 /PRNewswire/ --

Global Viral Vector and Plasmid Manufacturing Market to Reach $5.86 Billion by 2030

Read the full report: https://www.reportlinker.com/p05902571/?utm_source=PRN

Market Report Coverage - Viral Vector and Plasmid Manufacturing

Market Segmentation

Vector Type Plasmid DNA and Viral Vector Viral Vector Type Adenovirus, Adeno-Associated Virus, Retrovirus, Lentivirus, Vaccinia Virus, and Other Viral Vectors Disease Type Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, and Other Diseases Application Gene Therapy, Cell Therapy, Vaccinology, and Other Applications

Regional Segmentation North America U.S., Canada Europe Germany, U.K., France, Italy, Switzerland, Belgium, Spain, and Rest-of-Europe Asia-Pacific China, Australia, Japan, India, South Korea, Singapore, and Rest-of-Asia-Pacific Rest-of-the-World Latin America and Middle-East and Africa

Growth Drivers Rising Prevalence of Cancer, Genetic Disorders, and Infectious Diseases Rapid Uptake of Viral and Plasmid Vectors for the Development of Innovative Therapies Increasing Number of Clinical Studies for the Development of Gene Therapy Favorable Funding Scenario for Vector-Based Therapies

Market Challenges Unaffordable Cost of Gene Therapies High Manufacturing Costs of Viral Vectors and Plasmids Complications Associated with Large-Scale Production of Vectors

Market Opportunities Rising Demand for Synthetic Genes Emergence of Next-Generation Vectors

Key Companies ProfiledFUJIFILM Holdings Corporation, GENERAL ELECTRIC, Lonza, Merck KGaA, MolMed S.p.A., Novasep Holding, Oxford Biomedica plc, Catalent, Inc., Thermo Fisher Scientific, Inc., GenScript, Boehringer Ingelheim, Wuxi AppTec Co., Ltd., Sartorius AG, Takara Bio Inc., and Aldevron, L.L.C.

Key Questions Answered: What is a vector, and what is its importance in the medical industry? What are the major characteristics and types of vectors? What are the areas of application of vectors? What are the major advancements in the viral vector and plasmid manufacturing sector? What are the key trends of the global viral vector and plasmid manufacturing market? How is the market evolving and what is its future scope? What are the major drivers, challenges, and opportunities of the global viral vector and plasmid manufacturing market? What are the key developmental strategies implemented by the key players of the global viral vector and plasmid manufacturing market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies? What is the regulatory scenario of the global viral vector and plasmid manufacturing market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of viral vector and plasmid manufacturing products? What are major milestones in patenting activity in the global viral vector and plasmid manufacturing market? What was the market size of the global viral vector and plasmid manufacturing market in 2019, and what is the market size anticipated to be in 2030? What is the expected growth rate of the global viral vector and plasmid manufacturing market during the period between 2020 and 2030? What is the global market size for manufacturing plasmids and different types of viral vectors available in the global viral vector and plasmid manufacturing market in 2019? What are the key trends of the market with respect to different vectors and which vector type is expected to dominate the market during the forecast period 2020-2030? What are the different disease areas where plasmids and viral vectors are employed in the global viral vector and plasmid manufacturing market? Which disease type dominated the market in 2019 and is expected to dominate in 2030? What are the different applications associated with viral vector and plasmid manufacturing? What was the contribution of each of the application areas in the global viral vector and plasmid manufacturing market in 2019, and what is it expected in 2030? Which region is expected to contribute the highest sales to the global viral vector and plasmid manufacturing market during the period between 2019 and 2030? Which region and country carry the potential for significant expansion of key companies in the viral vector and plasmid manufacturing market? What are the leading countries of different regions that contribute significantly toward the growth of the market? Which are the key players of the global viral vector and plasmid manufacturing market, and what are their roles in the market? What was the market share of the key players in 2019?

Market OverviewThe ability of vectors to carry out genetic modification through the introduction of therapeutic DNA/gene into a patient's body or cell has enabled its application in a wide range of modern therapies, including cell and gene therapies.Growing prominence of these therapies in different medical applications has therefore resulted in an increased demand for both viral and non-viral vectors.

Vector-based therapies are currently being used for the treatment of a large number of diseases, including cancer, infectious diseases, genetic diseases, and cardiovascular diseases, among others.Viral vectors and plasmid reduce the cost of treatment and help in decreasing repeated administrations of medications.

Moreover, vectors are also increasingly being used in the field of vaccinology for the development of vaccines owing to the advantage offered by them in inducing a wide range of immune response types. Several players, including biopharmaceutical companies, research institutes, contract manufacturing organizations, and non-profit organizations, have therefore focussed their interest on the development and production of viral vectors and plasmids.

Our healthcare experts have found viral vector and plasmid manufacturing industry to be one of the most rapidly evolving markets, and the global market for viral vector and plasmid manufacturing is predicted to grow at a CAGR of 16.28% over the forecast period of 2020-2030. The market is driven by certain factors, which include success of vector-based cell and gene therapies in treating various therapeutic conditions, increasing number of clinical studies in the field of gene therapy and availability of funding for vector-based gene therapy development, technological advancements in the biomanufacturing sector, and growing investments for expanding vector manufacturing facilities.The market is favoured by the rising prevalence of genetic disorders, cancer, and infectious diseases that has raised the demand for advanced therapeutics and increasing acceptance for comparatively newer treatment options in developing countries.However, the growth of the market is also affected by several factors.

Exorbitant manufacturing cost and highly regulated processes for large-scale vector production are the key challenges cited by industry experts.In addition, lack of required infrastructure and the shortfall of expertise in terms of scale, complexities, and quality assurance for vector production are some of the factors restraining the market growth.

However, rise of contract manufacturers has effectively addressed the above-articulated manufacturing challenges by offering a wide range of vector manufacturing services that offer lucrative opportunities for the growth of the market. Further, increase in research and developmental activities in vector engineering offers strong promise to drive the growth of the viral vector and plasmid manufacturing market in the upcoming years.

Within the research report, the market is segmented on the basis of vector type, application, disease, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive LandscapeThe exponential rise in the application of viral vector and plasmid in various therapies on the global level has created a buzz among companies to invest significantly in viral vector and plasmid manufacturing market.The market is highly competitive, marking the presence of several contract manufacturing organizations and biopharmaceutical companies, who are engaged in in-house vector manufacturing.

Among the different players of the market, Lonza and Thermo Fisher Scientific hold majority of the market share. Other companies contributing significantly toward the growth of the global viral vector and plasmid manufacturing market include GE Healthcare, Fujifilm Holding Corporation, Merck KGaA, Oxford Biomedica plc, Sartorius AG, and Catalent, Inc., among others. On the basis of region, North America holds the largest market share, while Asia-Pacific is anticipated to grow at the fastest CAGR during the forecast period.

Countries Covered North America U.S. Canada Europe U.K. Germany France Spain Italy Switzerland Belgium Rest-of-Europe Asia-Pacific China Japan Australia South Korea India Singapore Rest-of-Asia-Pacific Rest-of-the-World

Read the full report: https://www.reportlinker.com/p05902571/?utm_source=PRN

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Continued here:
global market for viral vector and plasmid manufacturing is predicted to grow at a CAGR of 16.28% over the forecast period of 2020-2030 - Olean Times...

Read More...

On the Origins of Modern Biology and the Fantastic: Part 19 Nalo Hopkinson and Stem Cell Research – tor.com

Friday, May 29th, 2020

She just wanted to be somewhere safe, somewhere familiar, where people looked and spoke like her and she could stand to eat the food. Midnight Robber by Nalo Hopkinson

Midnight Robber (2000) is about a woman, divided. Raised on the high-tech utopian planet of Touissant, Tan-Tan grows up on a planet populated by the descendants of a Caribbean diaspora, where all labor is performed by an all-seeing AI. But when she is exiled to Touissants parallel universe twin planet, the no-tech New Half-Way Tree, with her sexually abusive father, she becomes divided between good and evil Tan-Tans. To make herself and New Half-Way Tree whole, she adopts the persona of the legendary Robber Queen and becomes a legend herself. It is a wondrous blend of science fictional tropes and Caribbean mythology written in a Caribbean vernacular which vividly recalls the history of slavery and imperialism that shaped Touissant and its people, published at a time when diverse voices and perspectives within science fiction were blossoming.

Science fiction has long been dominated by white, Western perspectives. Vernes tech-forward adventures and Wells sociological allegories established two distinctive styles, but still centered on white imperialism and class struggle. Subsequent futures depicted in Verne-like pulp and Golden Age stories, where lone white heroes conquered evil powers or alien planets, mirrored colonialist history and the subjugation of non-white races. The civil rights era saw the incorporation of more Wellsian sociological concerns, and an increase in the number of non-white faces in the future, but they were often tokensparts of a dominant white monoculture. Important figures that presaged modern diversity included Star Treks Lieutenant Uhura, played by Nichelle Nichols. Nichols was the first black woman to play a non-servant character on TV; though her glorified secretary role frustrated Nichols, her presence was a political act, showing there was space for black people in the future.

Another key figure was the musician and poet Sun Ra, who laid the aesthetic foundation for what would become known as the Afrofuturist movement (the term coined by Mark Dery in a 1994 essay), which showed pride in black history and imagined the future through a black cultural lens. Within science fiction, the foundational work of Samuel Delany and Octavia Butler painted realistic futures in which the histories and cultural differences of people of color had a place. Finally, an important modern figure in the decentralization of the dominant Western perspective is Nalo Hopkinson.

A similarly long-standing paradigm lies at the heart of biology, extending back to Darwins theoretical and Mendels practical frameworks for the evolution of genetic traits via natural selection. Our natures werent determined by experience, as Lamarck posited, but by genes. Therefore, genes determine our reproductive fitness, and if we can understand genes, we might take our futures into our own hands to better treat disease and ease human suffering. This theory was tragically over-applied, even by Darwin, who in Descent of Man (1871) conflated culture with biology, assuming the Wests conquest of indigenous cultures meant white people were genetically superior. After the Nazis committed genocide in the name of an all-white future, ideas and practices based in eugenics declined, as biological understanding of genes matured. The Central Dogma of the 60s maintained the idea of a mechanistic meaning of life, as advances in genetic engineering and the age of genomics enabled our greatest understanding yet of how genes and disease work. The last major barrier between us and our transhumanist future therefore involved understanding how genes determine cellular identity, and as well see, key figures in answering that question are stem cells.

***

Hopkinson was born December 20, 1960 in Kingston, Jamaica. Her mother was a library technician and her father wrote, taught, and acted. Growing up, Hopkinson was immersed in the Caribbean literary scene, fed on a steady diet of theater, dance, readings, and visual arts exhibitions. She loved to readfrom folklore, to classical literature, to Kurt Vonnegutand loved science fiction, from Spock and Uhura on Star Trek, to Le Guin, James Tiptree Jr., and Delany. Despite being surrounded by a vibrant writing community, it didnt occur to her to become a writer herself. What they were writing was poetry and mimetic fiction, Hopkinson said, whereas I was reading science fiction and fantasy. It wasnt until I was 16 and stumbled upon an anthology of stories written at the Clarion Science Fiction Workshop that I realized there were places where you could be taught how to write fiction. Growing up, her family moved often, from Jamaica to Guyana to Trinidad and back, but in 1977, they moved to Toronto to get treatment for her fathers chronic kidney disease, and Hopkinson suddenly became a minority, thousands of miles from home.

Development can be described as an orderly alienation. In mammals, zygotes divide and subsets of cells become functionally specialized into, say, neurons or liver cells. Following the discovery of DNA as the genetic material in the 1950s, a question arose: did dividing cells retain all genes from the zygote, or were genes lost as it specialized? British embryologist John Gurdon addressed this question in a series of experiments in the 60s using frogs. Gurdon transplanted nuclei from varyingly differentiated cells into oocytes stripped of their genetic material to see if a new frog was made. He found the more differentiated a cell was, the lower the chance of success, but the successes confirmed that no genetic material was lost. Meanwhile, Canadian biologists Ernest McCulloch and James Till were transplanting bone marrow to treat irradiated mice when they noticed it caused lumps in the mices spleens, and the number of lumps correlated with the cellular dosage. Their lab subsequently demonstrated that each lump was a clonal colony from a single donor cell, and a subset of those cells was self-renewing and could form further colonies of any blood cell type. They had discovered hematopoietic stem cells. In 1981 the first embryonic stem cells (ESCs) from mice were successfully propagated in culture by British biologist Martin Evans, winning him the Nobel Prize in 2007. This breakthrough allowed biologists to alter genes in ESCs, then use Gurdons technique to create transgenic mice with that alteration in every cellcreating the first animal models of disease.

In 1982, one year after Evans discovery, Hopkinson graduated with honors from York University. She worked in the arts, as a library clerk, government culture research officer, and grants officer for the Toronto Arts Council, but wouldnt begin publishing her own fiction until she was 34. [I had been] politicized by feminist and Caribbean literature into valuing writing that spoke of particular cultural experiences of living under colonialism/patriarchy, and also of writing in ones own vernacular speech, Hopkinson said. In other words, I had models for strong fiction, and I knew intimately the body of work to which I would be responding. Then I discovered that Delany was a black man, which opened up a space for me in SF/F that I hadnt known I needed. She sought out more science fiction by black authors and found Butler, Charles Saunders, and Steven Barnes. Then the famous feminist science fiction author and editor Judy Merril offered an evening course in writing science fiction through a Toronto college, Hopkinson said. The course never ran, but it prompted me to write my first adult attempt at a science fiction story. Judy met once with the handful of us she would have accepted into the course and showed us how to run our own writing workshop without her. Hopkinsons dream of attending Clarion came true in 1995, with Delany as an instructor. Her early short stories channeled her love of myth and folklore, and her first book, written in Caribbean dialect, married Caribbean myth to the science fictional trappings of black market organ harvesting. Brown Girl in the Ring (1998) follows a young single mother as shes torn between her ancestral culture and modern life in a post-economic collapse Toronto. It won the Aspect and Locus Awards for Best First Novel, and Hopkinson was awarded the John W. Campbell Award for Best New Writer.

In 1996, Dolly the Sheep was created using Gurdons technique to determine if mammalian cells also could revert to more a more primitive, pluripotent state. Widespread animal cloning attempts soon followed, (something Hopkinson used as a science fictional element in Brown Girl) but it was inefficient, and often produced abnormal animals. Ideas of human cloning captured the public imagination as stem cell research exploded onto the scene. One ready source for human ESC (hESC) materials was from embryos which would otherwise be destroyed following in vitro fertilization (IVF) but the U.S. passed the Dickey-Wicker Amendment prohibited federal funding of research that destroyed such embryos. Nevertheless, in 1998 Wisconsin researcher James Thomson, using private funding, successfully isolated and cultured hESCs. Soon after, researchers around the world figured out how to nudge cells down different lineages, with ideas that transplant rejection and genetic disease would soon become things of the past, sliding neatly into the hole that the failure of genetic engineering techniques had left behind. But another blow to the stem cell research community came in 2001, when President Bushs stem cell ban limited research in the U.S. to nineteen existing cell lines.

In the late 1990s, another piece of technology capturing the public imagination was the internet, which promised to bring the world together in unprecedented ways. One such way was through private listservs, the kind used by writer and academic Alondra Nelson to create a space for students and artists to explore Afrofuturist ideas about technology, space, freedom, culture and art with science fiction at the center. It was wonderful, Hopkinson said. It gave me a place to talk and debate with like-minded people about the conjunction of blackness and science fiction without being shouted down by white men or having to teach Racism 101. Connections create communities, which in turn create movements, and in 1999, Delanys essay, Racism and Science Fiction, prompted a call for more meaningful discussions around race in the SF community. In response, Hopkinson became a co-founder of the Carl Brandon society, which works to increase awareness and representation of people of color in the community.

Hopkinsons second novel, Midnight Robber, was a breakthrough success and was nominated for Hugo, Nebula, and Tiptree Awards. She would also release Skin Folk (2001), a collection of stories in which mythical figures of West African and Afro-Caribbean culture walk among us, which would win the World Fantasy Award and was selected as one ofThe New York Times Best Books of the Year. Hopkinson also obtained masters degree in fiction writing (which helped alleviate U.S. border hassles when traveling for speaking engagements) during which she wrote The Salt Roads (2003). I knew it would take a level of research, focus and concentration I was struggling to maintain, Hopkinson said. I figured it would help to have a mentor to coach me through it. That turned out to be James Morrow, and he did so admirably. Roads is a masterful work of slipstream literary fantasy that follows the lives of women scattered through time, bound together by the salt uniting all black life. It was nominated for a Nebula and won the Gaylactic Spectrum Award. Hopkinson also edited anthologies centering around different cultures and perspectives, including Whispers from the Cotton Tree Root: Caribbean Fabulist Fiction (2000), Mojo: Conjure Stories (2003), and So Long, Been Dreaming: Postcolonial Science Fiction & Fantasy (2004). She also came out with the award-winning novelThe New Moons Arms in 2007, in which a peri-menopausal woman in a fictional Caribbean town is confronted by her past and the changes she must make to keep her family in her life.

While the stem cell ban hamstrung hESC work, Gurdons research facilitated yet another scientific breakthrough. Researchers began untangling how gene expression changed as stem cells differentiated, and in 2006, Shinya Yamanaka of Kyoto University reported the successful creation of mouse stem cells from differentiated cells. Using a list of 24 pluripotency-associated genes, Yamanaka systematically tested different gene combinations on terminally differentiated cells. He found four genesthereafter known as Yamanaka factorsthat could turn them into induced-pluripotent stem cells (iPSCs), and he and Gurdon would share a 2012 Nobel prize. In 2009, President Obama lifted restrictions on hESC research, and the first clinical trial involving products made using stem cells happened that year. The first human trials using hESCs to treat spinal injuries happened in 2014, and the first iPSC clinical trials for blindness began this past December.

Hopkinson, too, encountered complications and delays at points in her career. For years, Hopkinson suffered escalating symptoms from fibromyalgia, a chronic disease that runs in her family, which interfered with her writing, causing Hopkinson and her partner to struggle with poverty and homelessness. But in 2011, Hopkinson applied to become a professor of Creative Writing at the University of California, Riverside. It seemed in many ways tailor-made for me, Hopkinson said. They specifically wanted a science fiction writer (unheard of in North American Creative Writing departments); they wanted someone with expertise working with a diverse range of people; they were willing to hire someone without a PhD, if their publications were sufficient; they were offering the security of tenure. She got the job, and thanks to a steady paycheck and the benefits of the mild California climate, she got back to writing. Her YA novel, The Chaos (2012), coming-of-age novelSister Mine (2013), and another short story collection, Falling in Love with Hominids (2015) soon followed. Her recent work includes House of Whispers (2018-present), a series in DC Comics Sandman Universe, the final collected volume of which is due out this June. Hopkinson also received an honorary doctorate in 2016 from Anglia Ruskin University in the U.K., and was Guest of Honor at 2017 Worldcon, a year in which women and people of color dominated the historically white, male ballot.

While the Yamanaka factors meant that iPSCs became a standard lab technique, iPSCs are not identical to hESCs. Fascinatingly, two of these factors act together to maintain the silencing of large swaths of DNA. Back in the 1980s, researchers discovered that some regions of DNA are modified by small methyl groups, which can be passed down through cell division. Different cell types have different DNA methylation patterns, and their distribution is far from random; they accumulate in the promoter regions just upstream of genes where their on/off switches are, and the greater the number of methyl groups, the lesser the genes expression. Furthermore, epigenetic modifications, like methylation, can be laid down by our environments (via diet, or stress) which can also be passed down through generations. Even some diseases, like fibromyalgia, have recently been implicated as such an epigenetic disease. Turns out that the long-standing biological paradigm that rejected Lamarck also missed the bigger picture: Nature is, in fact, intimately informed by nurture and environment.

In the past 150 years, we have seen ideas of community grow and expand as the world became more connected, so that they now encompass the globe. The histories of science fiction and biology are full of stories of pioneers opening new doorsbe they doors of greater representation or greater understanding, or bothand others following. If evolution has taught us anything, its that nature abhors a monoculture, and the universe tends towards diversification; healthy communities are ones which understand that we are not apart from the world, but of it, and that diversity of types, be they cells or perspectives, is a strength.

Kelly Lagor is a scientist by day and a science fiction writer by night. Her work has appeared at Tor.com and other places, and you can find her tweeting about all kinds of nonsense @klagor

See the original post here:
On the Origins of Modern Biology and the Fantastic: Part 19 Nalo Hopkinson and Stem Cell Research - tor.com

Read More...

COVID-19: Responding to the business impacts of CRISPR And CRISPR-Associated (Cas) Genes Market 2019 Trends, Size, Segments, Emerging Technologies and…

Friday, May 29th, 2020

A recent market study on the global CRISPR And CRISPR-Associated (Cas) Genes market reveals that the global CRISPR And CRISPR-Associated (Cas) Genes market is expected to reach a value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% during the forecast period (2019-2029).

The CRISPR And CRISPR-Associated (Cas) Genes market study includes a thorough analysis of the overall competitive landscape and the company profiles of leading market players involved in the global CRISPR And CRISPR-Associated (Cas) Genes market. Further, the presented study offers accurate insights pertaining to the different segments of the global CRISPR And CRISPR-Associated (Cas) Genes market such as the market share, value, revenue, and how each segment is expected to fair post the COVID-19 pandemic.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2649968&source=atm

The following doubts are addressed in the market report:

Key Highlights of the CRISPR And CRISPR-Associated (Cas) Genes Market Report

The presented report segregates the CRISPR And CRISPR-Associated (Cas) Genes market into different segments to ensure the readers gain a complete understanding of the different aspects of the CRISPR And CRISPR-Associated (Cas) Genes market.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2649968&source=atm

Segmentation of the CRISPR And CRISPR-Associated (Cas) Genes market

Competitive Outlook

This section of the report throws light on the recent mergers, collaborations, partnerships, and research and development activities within the CRISPR And CRISPR-Associated (Cas) Genes market on a global scale. Further, a detailed assessment of the pricing, marketing, and product development strategies adopted by leading market players is included in the CRISPR And CRISPR-Associated (Cas) Genes market report.

Sales and Pricing AnalysesReaders are provided with deeper sales analysis and pricing analysis for the global CRISPR And CRISPR-Associated (Cas) Genes market. As part of sales analysis, the report offers accurate statistics and figures for sales and revenue by region, by each type segment for the period 2015-2026.In the pricing analysis section of the report, readers are provided with validated statistics and figures for the price by players and price by region for the period 2015-2020 and price by each type segment for the period 2015-2020.Regional and Country-level AnalysisThe report offers an exhaustive geographical analysis of the global CRISPR And CRISPR-Associated (Cas) Genes market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of sales for the period 2015-2026.Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global CRISPR And CRISPR-Associated (Cas) Genes market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on sales by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global CRISPR And CRISPR-Associated (Cas) Genes market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global CRISPR And CRISPR-Associated (Cas) Genes market.The following manufacturers are covered in this report:Caribou BiosciencesAddgeneCRISPR THERAPEUTICSMerck KGaAMirus Bio LLCEditas MedicineTakara Bio USAThermo Fisher ScientificHorizon Discovery GroupIntellia TherapeuticsGE Healthcare DharmaconCRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by TypeGenome EditingGenetic engineeringgRNA Database/Gene LibrarCRISPR PlasmidHuman Stem CellsGenetically Modified Organisms/CropsCell Line EngineeringCRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by ApplicationBiotechnology CompaniesPharmaceutical CompaniesAcademic InstitutesResearch and Development Institutes

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2649968&licType=S&source=atm

Read the rest here:
COVID-19: Responding to the business impacts of CRISPR And CRISPR-Associated (Cas) Genes Market 2019 Trends, Size, Segments, Emerging Technologies and...

Read More...

High-Potency Pot Tied to Big Rise in Psychiatric Issues – HealthDay News

Friday, May 29th, 2020

FRIDAY, May 29, 2020 (HealthDay News) -- Marijuana has long been linked to a host of mental health risks, but the potent strains sold today may amplify those dangers, new research suggests.

"We know that people who use cannabis are more likely to report mental health problems than those who don't use cannabis, but we don't fully understand how recent increases in the strength and potency of cannabis affects this," explained study author Lindsey Hines, a senior research associate from the University of Bristol Medical School in England.

For the study, researchers examined data from a large, ongoing British study and focused on more than 1,000 people who were born in the early 1990s and reported recent pot use when they were 24. The scientists were also able to track which participants had suffered mental health problems as adolescents.

Among those who said they had used pot in the previous year, 13% said they had used high-potency cannabis.

Those who used high-potency pot were four times more likely to have problems with marijuana and two times more likely to suffer from anxiety than those who consumed lower-potency weed, the researchers found.

"People who use cannabis are more likely to report mental health problems than those who don't use cannabis, but reducing the potency and regularity of their cannabis use may be effective for lessening likelihood of harms from use," Hines said in a university news release.

"In countries where cannabis is sold legally, limiting the availability of high-potency cannabis may reduce the number of individuals who develop cannabis use disorders, prevent cannabis use escalating to a regular behavior, and reduce impacts on mental health," she added.

The report was published online May 28 in the journal JAMA Psychiatry.

This is not the first time marijuana has been tied to mental health problems: Research published in April in the journal Advances in Preventative Medicine found nearly half of people who have been or are now dependent on pot have some form of mental illness or dependence on another drug. That compares with 8% of people with no history of pot dependence.

Study author Esme Fuller-Thomson told HealthDay at the time that the study doesn't answer which came first, nor does it prove heavy pot use causes mental problems, but it does show a strong link.

"Not everyone that uses pot is going to develop mental health problems," said Fuller-Thomson, director of the Institute for Life Course and Aging at the University of Toronto.

Fuller-Thomson said she was concerned that legalization of pot will worsen mental health problems, especially among teens and young adults. Most users start as teens, and marijuana can harm the developing brain.

"My kids have to walk by three shops selling marijuana on their way to high school," she said. "We're now doing this very dangerous experiment on adolescents and young adults."

One psychiatrist agreed the trend is troubling.

As legalization of recreational marijuana spreads across the United States, more people are showing up in ERs with psychotic symptoms after consuming too much pot, said Dr. Itai Danovitch, chairman of psychiatry and behavioral neurosciences at Cedars-Sinai in Los Angeles.

"If somebody gets too high, they use more than intended, they can have psychotic symptoms. That typically resolves as the drug wears off," Danovitch said.

But some unlucky souls with a family history of mental illness might wind up with a full-fledged psychotic disorder that requires extended treatment, he noted.

"That risk is concentrated among a minority of people who have an existing vulnerability to develop a psychotic disorder, a family history of psychosis," Danovitch explained. "There are environmental factors that influence whether somebody develops schizophrenia who has a risk. It appears cannabis probably is one of those factors."

More information

For more on cannabis, head to the U.S. National Center for Complementary and Integrative Medicine.

SOURCES: University of Bristol, news release, May 28, 2020; Advances in Preventative Medicine, April 15, 2020

Read the original:
High-Potency Pot Tied to Big Rise in Psychiatric Issues - HealthDay News

Read More...

Anna Spivey named ND American Legionnaire of the Year – Cavalier County Extra

Friday, May 29th, 2020

You know her when you see her. What many may not know is that a common figure in the Langdon community was nominated by Langdon Post #98 to be the North Dakota American Legion Legionnaire of the Year. Anna Spivey was announced as the 2019 recipient of the Legionnaire of the Year Award in the March issue of the ND American Legion News publication.

I knew they had nominated me, but I was surprised I had won. I feel that people must appreciate what I do, but I just try to do for the Legion and the community what I can with no expectation of reward, Spivey said.

Anna has 23 continuous years of membership with Post #98 following a long involvement in military life as both an active duty member and spouse of an active member. She hasnt been as active as she has been in the past with involvement in the county museum, Frost Fire, and, of course, veteran-related activities such as American Legion and veteran services.

I do these things, and Im always trying to promote and make people aware of what is available in the community. The Legion has all these youth programs. I try to make sure that information is put out. I just try to benefit the community, Spivey shared.

Anna was raised in the Wales area and graduated from Langdon High School. Upon graduation, she entered the US Army and attended basic training at Ft. McClennan, Ala.. Upon completion she was trained in the medical field at Ft. Sam Houston, Texas, then on to Ft. Benning, Ga., where she worked as a health nurse and in preventative medicine.

My duty assignment was army health nurse. We taught prenatal classes for parents and did all the immunizations for military dependents of our service members. The army health nurse would do basically what a public health nurse does, Spivey explained.

During her time in the military, she met Linwood Spivey, a career soldier who was also in the medical field as a combat medic. They were married and became proud parents of two sons. Linwood served two tours in Vietnam, one in Korea and was stationed in Germany twice. Over the course of her husbands career, Spivey was active and involved in their military lifestyle wherever they were stationed.

I have always tried to be helpful to people. On the last tour to Germany, I was part of like the advisory board for our commissary which would be like our grocery store. I was asked to be on that board. I was active with the Red Cross, teaching first aide classes and CPR classes, Spivey said.

Post #98 Commander Harvey Metzger shared that the decision to nominate Spivey for the Legionnaire of the Year was easy. Her commitment to service, not only to the Legion but to the community, is shown when, on her own initiative, she promotes the activities of the American Legion. Spivey does this not only for the local Post events but those of the Department and National as well. Anna is a member of the Posts Color Guard and Honor Guard. She is always a volunteer in helping with Legion baseball, selling anniversary coins, and placing 'Helmets for Heroes' throughout the county. She is active in getting the word out for Boys and Girls State and the oratorical contest. She supports any of Post 98 activities and fundraisers, often providing suggestions for events that she feels strongly about holding.

You can always count on her at the local Post #98 to help out whenever needed. I believe women can make a difference in the American Legion. We appreciate her and her service, Metzger said.

Spivey would have been recognized during the American Legions Department Convention usually held in late June, but due the current health crisis, the convention has been canceled. Recognition for her achievement has left the humble Spivey at a loss for words and surprised as she always tried to operate under the radar.

I try to stay in the background. I just try to make sure the information is put out in the community - what is available to people. I also try to help as I can. Of course, now Im reaching an age where its more difficult, Spivey said.

Spivey tries to promote the Legion and other service organizations as much as she can. She wants to take the opportunity to encourage younger generations to participate and begin helping to serve their community. Spivey is ready to mentor anyone who is interested to learn how to become the next Legionnaire of the Year.

The rest is here:
Anna Spivey named ND American Legionnaire of the Year - Cavalier County Extra

Read More...

Major changes coming to Anderson health care in wake of virus – Independent Mail

Friday, May 29th, 2020

Mike Ellis, Anderson Independent Mail Published 7:43 a.m. ET May 28, 2020 | Updated 7:46 a.m. ET May 28, 2020

Autoplay

Show Thumbnails

Show Captions

This story is part of a series begun by USA TODAY capturing what America looks like as state economies slowly reopen. The Rebuilding America project examines what consumers can expect in key drivers of SC commerce.

Healthcare in Anderson County is likely to see fundamental changes in the wake of coronavirus.

Much of the fallout is not yet clear, but it will certainly accelerate telehealth, which isessentially meeting with doctors over video calls instead of in person, and will also accelerate changes in how billing works, said twoexperts from AnMed Health, Anderson County's main health care provider.

An independent physician, Dr. Shane Purcell, agreed those are the major two changes that can be predicted from the coronavirus pandemic at this time.

Purcell said that he would add a third change. His practice has been stable with no layoffsthroughout the coronavirus pandemic as other health systems, including AnMed Health, have had layoffs. Thatcould drive more health care providers and patients into practices like his.

Purcell is one of several doctors atDirect Access MD, an Anderson area family practice that operates outside of traditional insurance and government healthcare models and uses a membership model.

AnMed Health staff and bystanders take photos and video of F-16 planes from The South Carolina Air National Guard 169th Fighter Wing flying over the hospital in Anderson, S.C. Monday, April 27, 2020.(Photo: Ken Ruinard / staff)

Recent: AnMed Health to furlough employees, reduce salary of leadership because of coronavirus

Telehealth may be the most visible change to patients as medical offices go further and faster on long-existing trends in response to coronavirus concerns, said Michael Seemuller, a physician in family practice at Wren Medicine and chair of AnMed Health'sQuality and Safety Committee.

There are a lot of medical appointments that had been done in the past in person that can be done over a video chat, and it will likely become more widely used as people work to avoid potential infections and get comfortable with the format, he said.

The challenge with telehealth is that there is a lot that can be done remotely, such as routine visits, but there will always be people who need to see a doctor physically, for certain tests or checkups, Seemuller said.

Perhaps the biggest challenge, however, is access to telehealth, saidJuana Slade, chief diversity officer for AnMed Health.

She said she recently did a routine medical visit online, it took her 20 minutes.

But that is 20 minutes for someone who is familiar with computers, has the time and space to take 20 minutes and has Internet access that can often require money and locations that not everyone has, she said.

Fixing access in telehealth leads into the other major change, Sladesaid.

Virtual appointments: Coronavirus pandemic drives exponential growth of telehealth in the Upstate

The billing changes may not be as visible as telehealth to most people but may be more meaningful, the experts said.

AnMed Health, and other health systems,had already been working on value-based health care, which shiftsbilling from a per-procedure to an outcome-based billing process, Slade said.

The change will be driven by contractual incentives both from outside vendors and providers and from AnMed Health employees, she said.

Employees look at two wood pallets left on a wall on South Fant Street at AnMed Health, painted with words of encouragement and thanks in Anderson Thursday.(Photo: Ken Ruinard / staff)

If a hospital had been doing 100 of a given procedure with 85 good outcomes, it would have been paid more than if it did 90 of the same procedure with 85good outcomes. The new system aims to give contractual incentives on the outcome, rather than procedure side, and could result in fewer procedures being done because fewer are necessary, Slade said.

Doing fewer procedures would mean less income, illustrated by the furloughs at AnMed Health and in the broader health care economy. But changing the measurable to outcomes could lead to better health overall by nipping problems early, when they are cheaper, which also is better for people, Sladesaid. It also could help improve bottom-line revenue by reducing costs.

The change in emphasis to value-based billingcould help communities by focusing on underlying problems, shesaid.

Instead of treating heart attacks at the emergency room, typically the most expensive way to get health care, it would give AnMed Health incentives to treat a particular few blocks, for example, with preventative medicine like regular doctor's appointments that can be done virtually, Sladesaid.

The change won't be easy, and there are a lot of hurdles.

Slade estimates that 10 percent of health outcomes are up to the work of doctors and medical staff, the rest is the patient's responsibility, and a lot of the patient's outcome will be closely tied to factors like availability of healthy foods and good jobs, of education access and opportunities for health activities.

That means AnMed Health will be working a lot more with police and business communities to get those outcomes, Sladesaid.

Sarah Crowder of St. John's United Methodist Church decorate a cross with a white ribbon for health care workers to go with blue ribbons, before Maundy Thursday in the fellowship hall in Anderson Monday.(Photo: Ken Ruinard / staff)

And because much of this will tie back to regular, and increasingly virtual, doctor's visits, Internet access will be a big factor in any success.

The fallout from coronavirus has so far included furloughs for health care workers and others, it will likely have many other consequences for people's health and the financial structure of health care models in the country.

Many of those are unknown or subject to change, but an increase in telehealth and changes to billing structures are two fairly reliable predictions about the future of health care in Anderson County.

Read or Share this story: https://www.independentmail.com/story/news/2020/05/28/how-anderson-experts-see-healthcare-changing-due-coronavirus-telehealth/5178531002/

Go here to read the rest:
Major changes coming to Anderson health care in wake of virus - Independent Mail

Read More...

Page 3«..2345..1020..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick